Numerous preclinical studies have demonstrated that luminal breast cancer exhibits overactivity in the CDK4/6-cyclin D1 pathway, which provides a strong rationale for the therapeutic efficacy of CDK4/6 inhibitors (O’Sullivan et al., 2023). This evidence concerns the gene CDK4 and breast cancer.